ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $919,315 | -36.5% | 191,524 | -0.6% | 0.00% | – |
| Q2 2023 | $1,447,192 | +61.3% | 192,702 | -2.9% | 0.00% | – |
| Q1 2023 | $897,477 | -60.8% | 198,557 | -2.2% | 0.00% | – |
| Q4 2022 | $2,287,033 | -17.5% | 202,931 | -30.0% | 0.00% | -100.0% |
| Q3 2022 | $2,772,000 | +71.3% | 289,767 | +44.9% | 0.00% | – |
| Q2 2022 | $1,618,000 | -44.9% | 199,986 | +15.1% | 0.00% | -100.0% |
| Q1 2022 | $2,935,000 | -21.4% | 173,694 | -0.1% | 0.00% | 0.0% |
| Q4 2021 | $3,735,000 | -71.0% | 173,805 | -0.5% | 0.00% | -50.0% |
| Q3 2021 | $12,901,000 | +37.9% | 174,664 | +2.1% | 0.00% | 0.0% |
| Q2 2021 | $9,353,000 | -28.0% | 171,040 | -2.8% | 0.00% | 0.0% |
| Q1 2021 | $12,983,000 | +25.5% | 176,050 | +46.7% | 0.00% | 0.0% |
| Q4 2020 | $10,348,000 | +136.8% | 120,047 | +3.7% | 0.00% | +100.0% |
| Q3 2020 | $4,370,000 | – | 115,816 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |